# Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer

Source: https://onco.cc/trials/nct06702618/  
OnCo record `nct06702618` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Fulvestrant and TQB3616 in advanced solid tumours, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., active and no longer recruiting.

## Summary

Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer is a phase 2 interventional study registered as NCT06702618 by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., with 33 participants enrolled, started 2025-02-20 and due to reach its primary completion in 2026-06. Interventions recorded: TQB3616 capsule+Fulvestrant Injection.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06702618
- Phase: 2
- Setting: Evaluation of the Efficacy and Safety of TQB3616 Capsules Combined With Hormonal Therapy in a Phase II Clinical Trial for Cyclin-dependent Kinases 4 and 6（CDK4/6)Inhibitor-Resistant, Hormone Receptor(HR)-Positive, Human Epidermal Growth Factor Receptor 2(HER2)-Negative Recurrent/Metastatic Breast Cancer
- Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Enrolled: 33

## Sources

- ClinicalTrials.gov NCT06702618: https://clinicaltrials.gov/study/NCT06702618

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Fulvestrant](https://onco.cc/drugs/fulvestrant/), [TQB3616](https://onco.cc/drugs/tqb3616/)
- companies: [Sino Biopharmaceutical (Chia Tai Tianqing)](https://onco.cc/companies/sino-biopharm/)

---
JSON: https://onco.cc/api/v1/entities/nct06702618.json